Veracyte (VCYT) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $114.4 million, up 27–28% year-over-year, driven by strong Decipher Prostate and Afirma test volumes.

• Net income reached $5.7 million, with adjusted EBITDA of $24.0 million (21% margin), and significant improvement over Q2 2023.

• Ended Q2 with $235.9 million in cash and equivalents, generating $26.7 million in cash during the quarter.

• Completed the acquisition of C2i Genomics, expanding MRD detection capabilities.

• Raised full-year 2024 revenue guidance to $432–$438 million and year-end cash guidance to $260–$270 million.

Financial highlights

• Testing revenue grew 31% year-over-year to $107.0 million; product revenue was $3.9 million (down 3%); biopharma and other revenue was $3.6 million (down 22%).

• Gross margin improved to 68% (non-GAAP: 71%); testing gross margin was 74%.

• Operating income for Q2 2024 was $4.6 million; diluted EPS was $0.07; non-GAAP diluted EPS was $0.30.

• Cash provided by operations in Q2 was $29.6 million; net cash from operating activities for H1 2024 was $20.6 million.

Outlook and guidance

• Raised 2024 revenue guidance to $432–$438 million, up from $402–$410 million, with testing revenue expected to grow ~25%.

• Year-end 2024 cash, cash equivalents, and short-term investments expected at $260–$270 million.

• Forecasts sequential Q3 revenue decline due to seasonality and prior period collections, with Q4 expected to rebound.

• Ongoing investment in R&D, especially for MRD and IVD test development.